Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4494 Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,

#3781 Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) – Data from the national registry SEPTRALU

Introduction: PRRT is established in the treatment repertoire for advanced neuroendocrine neoplasms (NEN) expressing somatostatin receptors, without strong evidence for other factors influencing their activity.

Conference:

Presenting Author:

Authors: Bello P, Mitjavila Casanovas M, Jimenez-Fonseca P, Cabezas Agrícola J, Hernando Cubero J,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, PRRT, prognosis, radionuclide therapy, survival,

#3542 Essential role of nutritional support in patients with advanced carcinoid heart disease

Introduction: Chronic heart failure leads to cachexia in 5-15% of patients. Malnutrition affects 58% of patients with carcinoid syndrome.

Conference:

Presenting Author:

Authors: Shah H, Mair R, Arif S, Smith S, Vickrage S,

Keywords: carcinoid syndrome, carcinoid heart disease, nutrition, nasogastric feeding,

#3448 Differential diagnosis of diarrhoea in patients with neuroendocrine tumors

Introduction: Patients with neuroendocrine tumors (NETs) frequently experience diarrhoea that can impact their quality of life. Pancreatic enzyme insufficiency (PEI), bile acid diarrhoea (BAD) and small intestinal bacterial overgrowth (SIBO) are potential causes. There is a limited data on prevalence of these conditions in NETs.

Conference:

Presenting Author: Navaratnam J

Authors: Navaratnam J, Reed H, Sivananthan M, Rela A, Khan M,

Keywords: Neuroendocrine, Research, Diarrhoea, Quality of LIfe,